NPS PHARMACEUTICALS INC (NPSP)

HEALTH CARE: HEALTH CARE
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

550 HILLS DRIVE DRIVE BEDMINSTER, NJ 07921

NPS Pharmaceuticals discovers, develops and intends to commercialize small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. Its portfolio consists of an FDA-approved product and candidates in various stages of development.

View SEC Filings from NPSP instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NPSP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NPSP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BONNEY MICHAEL W

  • Director
No longer subject to file 2015-02-21 0

GRONINGER JAMES G

  • Director
No longer subject to file 2015-02-21 0

SELISKER RACHEL R

  • Director
No longer subject to file 2015-02-21 0

TOMBROS PETER G

  • Director
No longer subject to file 2015-02-21 0

NADER FRANCOIS PRESIDENT, CEO AND DIRECTOR

  • Officer
  • Director
No longer subject to file 2015-02-21 0

BESHAR LUKE M EVP & CFO

  • Officer
No longer subject to file 2015-02-21 0

GARCEAU ROGER SVP & CMO

  • Officer
No longer subject to file 2015-02-21 0

BROOM COLIN MD

  • Director
No longer subject to file 2015-02-21 0

ROGUS JOSEPH J SVP, GTO & SUPPLY CHAIN MNGMT

  • Officer
No longer subject to file 2015-02-21 0

GRANADILLO PEDRO P

  • Director
No longer subject to file 2015-02-21 0

PAUWELS ERIC PRESIDENT, NPS PHARMA INT'L

  • Officer
No longer subject to file 2015-02-21 0

GEMAYEL GEORGES

  • Director
No longer subject to file 2015-02-21 0

GRAF SUSAN E VP,CORP DEVELOPMENT & STRATEGY

  • Officer
0 2015-02-21 0

CVIJIC CHRISTINE MIKAIL SVP, LEGAL AFFAIRS & GC

  • Officer
No longer subject to file 2015-02-21 0

FRIEDMAN ROBIN D SVP OF HUMAN RESOURCES

  • Officer
0 2015-02-21 0

FIRUTA PAUL E PRESIDENT, US COMM OPERATIONS

  • Officer
0 2015-02-21 0

LEGAULT PIERRE

  • Director
No longer subject to file 2015-02-21 0

STRATEMEIER ED SVP & GENERAL COUNSEL

  • Officer
44,253 2014-02-13 0

MELROSE GLENN R SVP, HUMAN RESOURCES

  • Officer
26,971 2014-02-13 0

COTTRELL SANDRA VP, REGULATORY AFFAIRS & DRUG

  • Officer
0 2012-12-21 0

KUHLA DONALD E

  • Director
15,225 2012-02-07 0

BRYAN NANCY SVP, COMMERCIAL OPERATIONS

  • Officer
0 2011-02-17 0

RACKEAR ANDREW D. SVP, GENERAL COUNSEL & SEC.

  • Officer
0 2009-01-20 0

DOBAK DOUGLAS N VP, REGULATORY AFFAIRS

  • Officer
0 2008-10-15 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
No longer subject to file 2008-09-19 0

STILLER CALVIN

  • Director
0 2008-04-15 0

COLES N ANTHONY PRESIDENT, COO & DIRECTOR

  • Officer
  • Director
220,066 2008-03-17 0

HARRIS ALAN G SVP, CHIEF MEDICAL OFFICER

  • Officer
0 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments